✦ LIBER ✦

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

✍ Scribed by Aung Naing, Roger Cohen, Grace K. Dy, David S. Hong, Lyn Dyster, David G. Hangauer, Rudolf Kwan, Gerald Fetterly, Razelle Kurzrock, Alex A. Adjei…show all 10hide

Book ID: 120966762
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 144 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9929-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

390 A phase I trial of weekly AP23573, a

390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis

✍ A.A. Desai; L. Janisch; L. Berk; H.L. Knowles; V.M. Rivera; H.L. Kindler; W.M. S 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 142 KB

236 POSTER Phase I clinical trial of the

236 POSTER Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D cohort

✍ A. Townsend; P. Padrik; P. Mainwaring; T. Price; L. Catley; A. Longenecker; M.A. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB

395 POSTER Phase I study of XL844, a nov

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies

✍ A. Tse; S. Yazji; A. Naing; D. Matthews; G. Schwartz; K. Lawhorn; R. Kurzrock 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A first-in-class, first-in-human, phase

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

✍ Warso, M A; Richards, J M; Mehta, D; Christov, K; Schaeffer, C; Rae Bressler, L; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 748 KB